MacroGenics

MGNX

Market cap $88.6M

1.40 USD

-0.01

0.71%

At close Updated Dec 12, 4:00 PM EST

Pre-market

After hours

1.40

0.00

1 day

-0.71%

5 days

1 month

-4.76%

3 months

-11.95%

6 months

-9.68%

Year to date

-57.58%

1 year

-58.82%

5 years

-94.11%

10 years

-95.25%

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341

Healthcare Biotechnology